All In Biotech

Drug Trial Radar · NCT05203939

Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis

A Phase 1/2 Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa Associated With NR2E3 and RHO Mutations and Leber Congenital Amaurosis With Mutation(s) in CEP290 Gene

Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

22

Actual

Start

Jan 24, 2022

Primary completion

Mar 2027

Study completion Mar 2027

Sponsor

Lead sponsor
OcugenIndustry
Sponsor type
Industry
First posted
Jan 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU400 in patients with retinitis pigmentosa associated with NR2E3 and RHO mutations and in patients with LCA due to mutation(s) in CEP290 gene (OCU400-101). To document prospective eye pathology in the above subjects Investigators will also conduct a Natural History Study (OCU400-104)i This is a multicenter study, which will be conducted in two phases and will enroll up to a total of 24 subjects in the OCU400-101 and 100 subjects in the OCU400-104 study.

Conditions

  • Retinitis Pigmentosa
  • Leber Congenital Amaurosis

Interventions

  • OCU400 Low DoseDrug

    subretinal injection of up to 1.66×10E10 vg/mL

  • OCU400 Med DoseDrug

    subretinal injection of up to 3.33×10E10 vg/mL

  • OCU400 High DoseDrug

    subretinal injection of up to 1.66×10E11 vg/mL

  • OCU400 Second Eye DosingDrug

    subretinal injection of 1.0x10E11vg/mL in 250 μl

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Study Drug-related adverse events (SDAE)Time frame: 1 year
  2. Treatment-Emergent adverse events (TEAEs)Time frame: 1 year
  3. Serious adverse events (SAEs)Time frame: 1 year

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Associated Retina Consultants

    Phoenix, Arizona

  • Ocugen Site 5 - University of California, San Diego (UCSD) - Shiley Eye Institute

    La Jolla, California

  • Ocugen Site 3 - Bascom Palmer Eye Institute

    Miami, Florida

  • Ocugen Site 6 - Emory University

    Atlanta, Georgia

  • Ocugen Site 2 - Casey Eye Institute - OHSU

    Portland, Oregon

  • Ocugen Site 8 - Mid Atlantic Retina - Wills Eye Hospital

    Philadelphia, Pennsylvania

  • Ocugen Site 1 - Retina Foundation of the Southwest

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.